# Genscript Biotech Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genscript-biotech

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.genscript.com
- Total disclosed funding: $15M
- Latest round: Series A (Apr 15, 2009)
- Investors on record: 2

## About

Established in 2002 and headquartered in Nanjing, China, Genscript Biotech Corporation is a biotech enterprise that engages in drug development and cell therapy. In 2015, the company was listed in the Hong Kong Exchange Stock. Its stock code is 1548. In 2017, it acquired CustomArray. In 2019, the company established the European Regional Department and the Asia Pacific Regional Department. In 2022, Genscript Biotech Corporation established a production and R&D base in Singapore.

The company main operates four platforms include CRO (Contracted Research Organization) platform, CDMO (Contract Development and Manufacturing Organization) platform, industrial synthetic products platform and cell therapy platform. The CRO platform and CDMO platform provides drug development and production services. The industrial synthetic products platform develops products for food and feed processing. The cell therapy platform provides cell therapy solutions for patients with refractory diseases including cancer and inflammatory diseases.

In the future, the company will develop and expand production facilities.

## Funding rounds

- Series A, Apr 15, 2009, $15M — Kleiner Perkins, Shipston Group

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A
- Shipston Group (https://capitalatlas.ai/funds/shipston-group) — Series A